What were the key takeaways from Prothena's earnings call?

What does Prothena do and what are its main business segments?

What factors drove the changes in Prothena's revenue and profit?

What is the revenue and EPS growth rate for Prothena year over year?

What is Prothena's latest dividend and current dividend yield?

Did Prothena beat or miss consensus estimates last quarter?

What were the key takeaways from Prothena’s earnings call?

What is the market's earnings forecast for Prothena next quarter?

- **Birtamimab Pivotal Year:** Phase 3 AFFIRM-AL trial targeting 59% mortality risk reduction (VITAL trial p=0.021), with U.S. launch potential in H2 2026.
- **Alzheimer's Pipeline Expansion:** PRX012 Phase 1 data mid-2025, PRX123 Fast Track with IND cleared for Phase 1.
- **Commercial Ambition:** Birtamimab projected as multi-billion dollar opportunity with 2026 U.S. launch; Alzheimer's programs address underserved early/symptomatic AD markets.
- **Financial Strength:** $472M cash as of Dec 2024, well-capitalized for 2025 ($171.5M net cash use) with no debt.

**【CEO Opening Remarks】**
- Prothena's mission is to develop transformational therapies for protein dysregulation diseases, with a focus on neurodegenerative and rare peripheral amyloid diseases.
- 2025 is a pivotal year with key readouts for wholly-owned programs: birtamimab (AL amyloidosis), PRX012 (Alzheimer's), and PRX123 (dual A-beta/tau vaccine).
- Birtamimab Phase 3 AFFIRM-AL trial expected to report Q2 2025, with potential U.S. launch in H2 2026 if successful.

**【Chad Swanson - Clinical Updates】**
- **Birtamimab (AL amyloidosis):**
  - Confirmatory Phase 3 AFFIRM-AL trial randomized 2:1, with primary endpoint of time to all-cause mortality (p ≤ 0.10 for success).
  - VITAL trial showed 59% risk reduction in Mayo Stage IV patients (p=0.021), supporting SPA agreement with FDA.
  - Coramitug (ATTR-CM) Phase 2 signal detection trial by Novo Nordisk expected to report H2 2025.
- **Alzheimer's Portfolio:**
  - PRX012 Phase 1 ASCENT-2 trial evaluating safety and PK/PD in early AD patients, with mid-2025 data readout.
  - PRX123 dual A-beta/tau vaccine granted Fast Track designation, with IND cleared for Phase 1.

**【Brandon Smith - Commercial Strategy】**
- **Birtamimab Market Potential:**
  - U.S. diagnosed and treated AL amyloidosis patients: ~16,000 (13,000 with cardiac involvement).
  - Peak penetration expected in Mayo Stage IV patients (~5,000 U.S., 5,000 Europe), with multi-billion dollar global opportunity.
  - Launch strategy: focused sales force targeting amyloidosis centers of excellence.
- **Alzheimer's Pipeline:**
  - PRX012 positioned for early AD market with once-monthly subcutaneous administration.
  - PRX123 vaccine approach targeting presymptomatic and early symptomatic AD populations.

**【Tran Nguyen - Financial Performance】**
- **2024 Results:**
  - Net cash used: $150.3M (low end of $148-160M guidance).
  - Net loss: $122.3M (low end of $120-135M guidance).
  - Cash balance: $472.2M as of Dec 31, 2024.
- **2025 Guidance:**
  - Net cash used: $168-175M (midpoint $171.5M).
  - Ending cash: ~$301M (midpoint of $297-305M range).
  - Key driver: estimated net loss of $197-205M, including $41M non-cash SBC.

**【Q&A Highlights】**
- **Birtamimab Market Dynamics:**
  - 80% of AFFIRM-AL patients on daratumumab, but no impact on early mortality (ANDROMEDA trial p=0.0657).
  - High demand for anti-amyloid therapy with favorable safety profile in high-risk patients.
- **PRX012 Development:**
  - ASCENT-2 trial expansion cohort (200mg, ~100 patients) to better characterize PK/PD and safety in APOE4 homozygous carriers.
  - Long-term data from ASCENT-3 open-label extension to inform Phase 2 design.
- **Regulatory Pathway:**
  - FDA SPA agreement for birtamimab requires p ≤ 0.10 for BLA submission; European regulators expected to align on risk-benefit profile.

PRTA

PRTA fundamentals

Earnings Call

You can ask Aime